March 26, 2012 — Itamar-Medical unveiled its cardiovascular healthcare assessment platform, EndoPAT-MF, at the American College of Cardiology’s 61st Annual Scientific Session (ACC.12) in Chicago. The multifunction EndoPAT-MF now features five major diagnostic tools in a single system. In addition to providing the only U.S. Food and Drug Administration (FDA)-cleared, non-invasive measure of endothelial function, the platform also features an augmentation index measuring arterial stiffness and heart rate variability (offering a window onto the autonomic nervous system), as well as leading risk score calculators (Framingham, Reynolds and SCORE) and an integrated Web-based platform, EndoCloud, to provide seamless and efficient patient diagnosis information transfer in a timely manner.
“The fact that heart disease starts in the arteries and blood vessels makes EndoPAT a critical tool for early detection and continued physiological assessment of the health of the vascular system. More than half of all sudden cardiac deaths occur with no previous symptoms and cardiovascular disease continues to be the leading health risk in the United States. Our continued enhancements to EndoPAT offer a significant value in this next-generation tool set for early detection and analysis for patient, payer, provider, and physician,” said Marvin Slosman, president of Itamar-Medical Inc. in the United States.
The EndoPAT-MF will be available upon meeting the regulatory requirements in each of the international geographies. The integrated platform will enable all users to benefit from convenience and cost savings by performing the diagnostic tasks of several devices on a single, unified platform.
For more information: www.itamar-medical.com
August 15, 2024 
